AllAnalyst Report
Morningstar•December 07, 2021
Morningstar•December 07, 2021Guardant Health, Inc.: Guardant Health's Early-Stage Pipeline Shows Promise, Supports Positive Moat Trend
Summary
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individua
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- TRUP: Lowering target price to $18.00Apr 17, 2024 •
TRUP, DXCM
- DXCM: Lowering target price to $143.00Apr 17, 2024 •
DXCM
- QDEL: Lowering target price to $32.00Apr 17, 2024 •
QDEL
- SWAV: Rating increased to a HOLDApr 17, 2024 •
SWAV
- MYGN: Lowering target price to $20.00Apr 17, 2024 •
MYGN
Analyst Profile
Aaron Degagne
Equity AnalystAaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.